|
1
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim VN and Nam JW: Genomics of microRNA.
Trends Genet. 22:165–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar
|
|
6
|
Kerr TA, Korenblat KM and Davidson NO:
MicroRNAs and liver disease. Transl Res. 157:241–252. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
8
|
Takahashi K, Yan I, Wen HJ and Patel T:
microRNAs in liver disease: from diagnostics to therapeutics. Clin
Biochem. 46:946–952. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sachdeva M and Mo YY: miR-145-mediated
suppression of cell growth, invasion and metastasis. Am J Transl
Res. 2:170–180. 2010.PubMed/NCBI
|
|
10
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao C, Xu Y, Zhang Y, et al:
Downregulation of miR-145 contributes to lung adenocarcinoma cell
growth to form brain metastases. Oncol Rep. 30:2027–2034.
2013.PubMed/NCBI
|
|
12
|
Havelange V, Stauffer N, Heaphy CC, et al:
Functional implications of microRNAs in acute myeloid leukemia by
integrating microRNA and messenger RNA expression profiling.
Cancer. 117:4696–4706. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sachdeva M and Mo YY: MicroRNA-145
suppresses cell invasion and metastasis by directly targeting mucin
1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gregersen LH, Jacobsen AB, Frankel LB, Wen
J, Krogh A and Lund AH: MicroRNA-145 targets YES and
STAT1 in colon cancer cells. PLoS One. 5:e88362010.
View Article : Google Scholar
|
|
15
|
Noh JH, Chang YG, Kim MG, et al: MiR-145
functions as a tumor suppressor by directly targeting histone
deacetylase 2 in liver cancer. Cancer Lett. 335:455–462. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho WC, Chow AS and Au JS: MiR-145
inhibits cell proliferation of human lung adenocarcinoma by
targeting EGFR and NUDT1. RNA Biol. 8:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee HK, Bier A, Cazacu S, et al:
MicroRNA-145 is downregulated in glial tumors and regulates glioma
cell migration by targeting connective tissue growth factor. PLoS
One. 8:e546522013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Doberstein K, Steinmeyer N, Hartmetz AK,
et al: MicroRNA-145 targets the metalloprotease ADAM17 and is
suppressed in renal cell carcinoma patients. Neoplasia. 15:218–230.
2013.PubMed/NCBI
|
|
19
|
Lu Y, Chopp M, Zheng X, Katakowski M,
Buller B and Jiang F: MiR-145 reduces ADAM17 expression and
inhibits in vitro migration and invasion of glioma cells.
Oncol Rep. 29:67–72. 2013.PubMed/NCBI
|
|
20
|
Yang XW, Zhang LJ, Huang XH, et al:
miR-145 suppresses cell invasion in hepatocellular carcinoma cells:
miR-145 targets ADAM17. Hepatol Res. 44:551–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Black RA, Rauch CT, Kozlosky CJ, et al: A
metalloproteinase disintegrin that releases tumour-necrosis
factor-α from cells. Nature. 385:729–733. 1997.
|
|
22
|
Mohan MJ, Seaton T, Mitchell J, et al: The
tumor necrosis factor-α converting enzyme (TACE): a unique
metalloproteinase with highly defined substrate selectivity.
Biochemistry. 41:9462–9469. 2002.
|
|
23
|
Zheng X, Jiang F, Katakowski M, Zhang ZG,
Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant
phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther.
8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng X, Jiang F, Katakowski M, Lu Y and
Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol
Carcinog. 51:150–164. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee SO, Jeong YJ, Yu MH, et al: Wogonin
suppresses TNF-α-induced MMP-9 expression by blocking the NF-κB
activation via MAPK signaling pathways in human aortic smooth
muscle cells. Biochem Biophys Res Commun. 351:118–125. 2006.
|
|
26
|
Balasubramanian S, Fan M, Messmer-Blust
AF, et al: The interferon-γ-induced GTPase, mGBP-2, inhibits tumor
necrosis factor α (TNF-α) induction of matrix metalloproteinase-9
(MMP-9) by inhibiting NF-κB and Rac protein. J Biol Chem.
286:20054–20064. 2011.
|
|
27
|
Li YQ, Yan JP, Xu WL, et al: ADAM17
mediates MMP9 expression in lung epithelial cells. PLoS One.
8:e517012013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elbashir SM, Harborth J, Weber K and
Tuschl T: Analysis of gene function in somatic mammalian cells
using small interfering RNAs. Methods. 26:199–213. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krek A, Grün D, Poy MN, et al:
Combinatorial microRNA target predictions. Nat Genet. 37:495–500.
2005. View
Article : Google Scholar
|
|
30
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human microRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar
|
|
31
|
Yu Q and Stamenkovic I: Cell
surface-localized matrix metalloproteinase-9 proteolytically
activates TGF-β and promotes tumor invasion and angiogenesis. Genes
Dev. 14:163–176. 2000.PubMed/NCBI
|
|
32
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo
YY: MicroRNA-21 targets tumor suppressor genes in invasion and
metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kusenda B, Mraz M, Mayer J and Pospisilova
S: MicroRNA biogenesis, functionality and cancer relevance. Biomed
Pap Med Fac Univ Palacky Olomouc Czech Repub. 150:205–215. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McGowan PM, Ryan BM, Hill AD, McDermott E,
O’Higgins N and Duffy MJ: ADAM-17 expression in breast cancer
correlates with variables of tumor progression. Clin Cancer Res.
13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kenny PA and Bissell MJ: Targeting
TACE-dependent EGFR ligand shedding in breast cancer. J Clin
Invest. 117:337–345. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Borrell-Pagès M, Rojo F, Albanell J,
Baselga J and Arribas J: TACE is required for the activation of the
EGFR by TGF-α in tumors. EMBO J. 22:1114–1124. 2003.
|
|
38
|
Karbiener M, Pisani DF, Frontini A, et al:
MicroRNA-26 family is required for human adipogenesis and drives
characteristics of brown adipocytes. Stem Cells. 32:1578–1590.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen YJ and Chang LS: Hydroquinone-induced
miR-122 down-regulation elicits ADAM17 up-regulation, leading to
increased soluble TNF-α production in human leukemia cells with
expressed Bcr/Abl. Biochem Pharmacol. 86:620–631. 2013.PubMed/NCBI
|
|
40
|
Tsai WC, Hsu PW, Lai TC, et al:
MicroRNA-122, a tumor suppressor microRNA that regulates
intrahepatic metastasis of hepatocellular carcinoma. Hepatology.
49:1571–1582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Das S, Czarnek M, Bzowska M, et al: ADAM17
silencing in mouse colon carcinoma cells: the effect on tumoricidal
cytokines and angiogenesis. PLoS One. 7:e507912012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xiao LJ, Lin P, Lin F, et al: ADAM17
targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to
promote prostate cancer cell invasion. Int J Oncol. 40:1714–1724.
2012.PubMed/NCBI
|
|
43
|
Mattu TS, Royle L, Langridge J, et al:
O-glycan analysis of natural human neutrophil gelatinase B using a
combination of normal phase-HPLC and online tandem mass
spectrometry: implications for the domain organization of the
enzyme. Biochemistry. 39:15695–15704. 2000. View Article : Google Scholar
|
|
44
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bauvois B: New facets of matrix
metalloproteinases MMP-2 and MMP-9 as cell surface transducers:
outside-in signaling and relationship to tumor progression. Biochim
Biophys Acta. 1825:29–36. 2012.
|
|
46
|
Klein T and Bischoff R: Physiology and
pathophysiology of matrix metalloproteases. Amino Acids.
41:271–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
